Validating CaMKK2 As A Rational Treatment Target For Bipolar Disorder
Funder
National Health and Medical Research Council
Funding Amount
$688,175.00
Summary
Bipolar disorder is a disabling, chronic mental illness that profoundly impairs the ability of affected individuals to function in daily life. Existing treatments for bipolar disorder are inadequate and lack the necessary efficacy and tolerability required for long-term therapy. This project will validate the enzyme, CaMKK2, as a rational treatment target for bipolar disorder, which will guide the development of more effective and safer drugs to improve patient outcomes.
Understanding Epigenetic Modification During Oogenesis For Novel Treatments Of Female Infertility
Funder
National Health and Medical Research Council
Funding Amount
$314,644.00
Summary
Infertility affects about 10% of Australian women and the success rates of current infertility treatments are low due to our poor knowledge of eggs development. The numbers of obese and older women trying to conceive are increasing; fertility treatments are even less effective for them. I have generated mouse models to elucidate the pathways regulating egg development. I will study for alterations in these pathways in the mouse models which perfectly mimic the obesity and aging in women.
Transcriptional Effectors Of Oncogenic ERK Signaling In Colorectal Cancer
Funder
National Health and Medical Research Council
Funding Amount
$820,776.00
Summary
This project aims to unravel how one of the most frequently deregulated molecular pathways in colorectal cancer controls the expression of genes required for these tumours to grow and spread. We expect this work to uncover novel therapeutic targets to effectively inactivate this pathway and biomarkers to select patients most likely to benefit from existing therapies.
Psychiatric disorders in epilepsy. Psychiatric disorders, such as depression, anxiety and cognitive disorders, are frequently observed in patients with epilepsy. Although standard dogma suggests that psychiatric disorders are a consequence of living with epilepsy, recent evidence suggests a bidirectional relationship between these disorders, such that depression and other psychiatric illnesses act as risk factors for epilepsy development. This project will utilise basic science approaches to und ....Psychiatric disorders in epilepsy. Psychiatric disorders, such as depression, anxiety and cognitive disorders, are frequently observed in patients with epilepsy. Although standard dogma suggests that psychiatric disorders are a consequence of living with epilepsy, recent evidence suggests a bidirectional relationship between these disorders, such that depression and other psychiatric illnesses act as risk factors for epilepsy development. This project will utilise basic science approaches to understand the causal relationships between epilepsy and psychiatric disorders, and determine how and why psychiatric disorders and epilepsy co-exist. It is hoped that research conducted in this project will develop novel avenues to treatment of both epilepsy and psychiatric disorders.Read moreRead less
UNDERSTANDING THE BASIS OF COMPLEX BEHAVIOUR. This project is anchored in the fundamental understanding of complex vertebrate behaviours, namely cognition. Little is known about the molecular and neural substrates underpinning complex higher order information processing. This project aims to dissect the functional role of synaptic genes that are essential for organising neuronal connections, in distinct cognitive processes and how these functions may be regulated by other genes, drugs or environ ....UNDERSTANDING THE BASIS OF COMPLEX BEHAVIOUR. This project is anchored in the fundamental understanding of complex vertebrate behaviours, namely cognition. Little is known about the molecular and neural substrates underpinning complex higher order information processing. This project aims to dissect the functional role of synaptic genes that are essential for organising neuronal connections, in distinct cognitive processes and how these functions may be regulated by other genes, drugs or environmental factors. This project aims to employ state-of-the-art technologies to address the evolutionary biology of complex cognitive behaviours, towards further understandings how brain function evolved and the mechanisms that have enabled humans to perform highly complex and intricate tasks.Read moreRead less
ROLE OF RIP KINASES & IAPs IN MUCOSAL IMMUNE DEFENCE
Funder
National Health and Medical Research Council
Funding Amount
$631,168.00
Summary
Pathogenic bacteria are master manipulators of the inflammatory signalling pathways designed to thwart them. Understanding how they do this will allow us to develop drugs that limit their ability to infect. We have shown that pathogenic bacteria inject a protein called EspL into human cells to promote the destruction of a family of human proteins, called RIP Kinases (RIPK), that co-ordinate the inflammatory response and aim now to discover how EspL causes RIPK degradation and thereby promotes in ....Pathogenic bacteria are master manipulators of the inflammatory signalling pathways designed to thwart them. Understanding how they do this will allow us to develop drugs that limit their ability to infect. We have shown that pathogenic bacteria inject a protein called EspL into human cells to promote the destruction of a family of human proteins, called RIP Kinases (RIPK), that co-ordinate the inflammatory response and aim now to discover how EspL causes RIPK degradation and thereby promotes infection.Read moreRead less
The Importance Of Receptor Trafficking For Signalling Of Pain And Inflammation
Funder
National Health and Medical Research Council
Funding Amount
$787,604.00
Summary
Inflammation and pain are normal processes that are essential for survival: inflammation fights infections and pain allows avoidance of danger. These processes are normally tightly controlled and are transient. During disease, they become dysregulated and chronic. By understanding the normal processes of inflammation and pain, and by determining how dysregulation causes disease, we aim to develop new treatments for diseases that are a major cause of human suffering.
I am a neuroscientist employing strategies of anatomy, biochemistry, pharmacology, genetics and behavioural analysis to examine the physiological and possible pathological roles of newly discovered neuropeptides and their cognate receptors in mammalian brain. My recent research has focused on the highly-conserved, abundant peptide, relaxin-3 that was discovered at the HFI in 2002. Studies so far have revealed that relaxin-3 is a powerful modulator of rhythmic brain activity (theta) and spatial m ....I am a neuroscientist employing strategies of anatomy, biochemistry, pharmacology, genetics and behavioural analysis to examine the physiological and possible pathological roles of newly discovered neuropeptides and their cognate receptors in mammalian brain. My recent research has focused on the highly-conserved, abundant peptide, relaxin-3 that was discovered at the HFI in 2002. Studies so far have revealed that relaxin-3 is a powerful modulator of rhythmic brain activity (theta) and spatial memory, and alters feeding, body weight and arousal. Relaxin-3 levels in brain are also strongly activated by acute stress. In the future, I aim to elucidate further the role of relaxin-3 systems in normal physiology and metabolic and-or psychiatric diseases.Read moreRead less
The role of synapse development in cognitive disorder. In humans, intellectual disability occurs when nerve cells in the brain fail to connect. The project examines fundamental molecular processes involved in synapse development of neurons. The use of insect models provides a generalised biological template to understand how synaptic molecules contribute to behaviours that underlie cognitive disorder.
Targeted Development Of AMPK Β2-isoform Allosteric Activators
Funder
National Health and Medical Research Council
Funding Amount
$898,147.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to dramatic increases in the incidence of diseases associated with metabolic dysregulation e.g. type 2 diabetes. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as a cellular fuel gauge. We have discovered a new drug that crucially activates the form of AMPK found in metabolically active organs. We aim to develop this drug to unlock new therapeutic opportunity.